How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Fruquintinib for previously treated metastatic colorectal cancer

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about fruquintinib

Marketing authorisation indication

2.1

Fruquintinib (Fruzaqla, Takeda) is indicated for 'the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and if RAS wildtype and medically appropriate, an anti-EGFR therapy'.

Dosage in the marketing authorisation

2.2

The dosage schedule will be available in the summary of product characteristics for fruquintinib.

Price

2.3

The list price of fruquintinib is confidential until the final guidance is published.

2.4

The company has a commercial arrangement, which would have applied if fruquintinib had been recommended.